Xilio Therapeutics Ownership | Who Owns Xilio Therapeutics?
Xilio Therapeutics Ownership Summary
Xilio Therapeutics is owned by 14.21% institutional investors, 25.98% insiders, and 59.81% retail investors. Rivervest venture management is the largest institutional shareholder, holding 5.16% of XLO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.17% of its assets in Xilio Therapeutics shares.
XLO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Xilio Therapeutics | 14.21% | 25.98% | 59.81% |
| Sector | Healthcare Stocks | 244.59% | 12.11% | -156.70% |
| Industry | Biotech Stocks | 379.61% | 11.70% | -291.31% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Rivervest venture management | 1.44M | 5.16% | $1.37M |
| Takeda pharmaceutical | 1.48M | 1.53% | $1.24M |
| Vanguard group | 1.26M | 0.87% | $803.64K |
| Gilead sciences | 650.39K | 0.78% | $5.47M |
| Balyasny asset management | 198.86K | 0.27% | $135.20K |
| Blackrock | 66.42K | 0.24% | $62.93K |
| Raymond james & associates | 38.83K | 0.14% | $36.79K |
| Susquehanna group, llp | 49.09K | 0.08% | $46.88K |
| Charles schwab investment management | 11.93K | 0.04% | $11.30K |
| Two sigma securities | 32.13K | 0.03% | $27.08K |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Rivervest venture management | 1.44M | 20.01% | $1.37M |
| Takeda pharmaceutical | 1.48M | 7.59% | $1.24M |
| Gilead sciences | 650.39K | 0.26% | $5.47M |
| Two sigma securities | 32.13K | 0.00% | $27.08K |
| Balyasny asset management | 198.86K | 0.00% | $135.20K |
| Two sigma advisers, lp | 29.69K | 0.00% | $25.02K |
| Engineers gate manager lp | - | - | - |
| Mariner | - | - | - |
| Caligan partners lp | - | - | - |
| Blackrock | 66.42K | - | $62.93K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Susquehanna group, llp | 49.09K | - | 49.09K |
| Raymond james & associates | 38.83K | - | 38.83K |
| Two sigma securities | 32.13K | 0.00% | 32.13K |
| Two sigma advisers, lp | 29.69K | 0.00% | 29.69K |
| Blackrock | 66.42K | - | 21.06K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Gilead sciences | 650.39K | 0.26% | -8.46M |
| Bain capital life sciences investors | - | - | -7.37M |
| Frazier life sciences management | - | - | -5.92M |
| Point72 asset management | - | - | -4.00M |
| Rock springs capital management lp | - | - | -3.00M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Susquehanna group, llp | 49.09K | - | 49.09K | $46.88K |
| Raymond james & associates | 38.83K | - | 38.83K | $36.79K |
| Two sigma securities | 32.13K | 0.00% | 32.13K | $27.08K |
| Two sigma advisers, lp | 29.69K | 0.00% | 29.69K | $25.02K |
Sold Out
| Holder | Change |
|---|---|
| Qube research | -4.00 |
| Royal bank of canada | -91.00 |
| Wells fargo & company/mn | -108.00 |
| Ubs group | -203.00 |
| Vanguard global advisers | -210.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 25 | 4.17% | 2,756,592 | 5.23% | 14 | 7.80% | 14 | 75.00% | 4 | -75.00% |
| Mar 31, 2026 | 1 | -97.30% | 650,389 | -98.36% | - | 0.10% | - | -100.00% | 1 | -80.00% |
| Dec 31, 2025 | 22 | -38.89% | 20,254,500 | -8.15% | 14 | 2.69% | 8 | -27.27% | 3 | - |
| Sep 30, 2025 | 36 | 5.88% | 22,051,916 | -1.34% | 22 | 2.55% | 11 | 10.00% | 3 | -72.73% |
| Jun 30, 2025 | 34 | 3.03% | 23,770,263 | 21.47% | 31 | 4.64% | 11 | -21.43% | 10 | 42.86% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 142.44K | 2.17% | 80.98K |
| Vanguard Morn Total Stk Mkt Idx Investor | 142.44K | 2.17% | 80.98K |
| Vanguard MStar Total Stk Mkt Idx Invest | 142.44K | 2.16% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 35.61K | 0.54% | - |
| Fidelity Extended Market Index | 19.50K | 0.30% | -326.00 |
| Bridgeway Ultra-Small Company | 17.54K | 0.27% | 17.54K |
| Abante Quant Value FI | 15.63K | 0.24% | - |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 13.05K | 0.22% | - |
| iShares Micro-Cap ETF | 8.11K | 0.12% | -108.00 |
| NT Ext Equity Mkt Index Fund - Lending | 5.91K | 0.09% | 3.69K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 26, 2026 | Shannon James Samuel | - | Buy | $43.95K |
| Feb 13, 2026 | GILEAD SCIENCES, INC. | - | Buy | $373.90 |
| Jan 02, 2026 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Sell | $1.17K |
| Jan 02, 2026 | Frankenfield Christopher James | Chief Financial Officer | Sell | $4.52K |
| Jun 17, 2025 | Shannon James Samuel | - | Buy | $17.21K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | - |
| 2026 Q1 | 2 | 2 |
| 2025 Q4 | - | - |
| 2025 Q2 | 7 | - |
| 2025 Q1 | - | 2 |
XLO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools